A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorPeking University First Hospital
About this trial
Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden.
Eligibility criteria
Qualifiers
Signed informed consent;
Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV);
Age 18-75 years;
Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months);
Disqualifiers
Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;
Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;
Combined with other malignant tumors, still receiving anti-tumor therapy;
Comorbid epilepsy;
Trial design
Treatments tested in this trial
- molecular subtype based treatment
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking University First Hospital
Lead sponsor
Peking University Third Hospital
Collaborator
Peking University Cancer Hospital & Institute
Collaborator
Source ClinicalTrials.gov